Diagnosis and therapy of cutaneous and mucocutaneous Leishmaniasis in Germany;Diagnostik und Therapie der kutanen und mukokutanen Leishmaniasis in Deutschland

JDDG - Journal of the German Society of Dermatology

Volumn 9, Issue SUPPL.8, 2011, Pages 1-51

  Boecken, Gerhard ^a   Sunderkötter, Cord ^b   Bogdan, Christian ^c   Weitzel, Thomas ^d,m   Fischer, Marcellus ^e   Müller, Andreas ^f   Löbermann, Micha ^g   Anders, Gerlind ^a   Von Stebut, Esther ^h   Schunk, Mirjam ⁱ   Burchard, Gerd ^j   Grobusch, Martin ^k   Bialek, Ralf ^l   Harms Zwingenberger, Gundel ^m   Fleischer, Bernhard ^e   Pietras, Mathias ^a   Faulde, Michael ⁿ   Erkens, Kay ^o  

^a Regionalarztdienststelle Ostafrika ^*  (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSIDAD DEL DESARROLLO   (Chile)

^e BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^f Missionsarztliche Klinik   (Germany)

^g UNIVERSITY OF ROSTOCK   (Germany)

^h JOHANNES GUTENBERG UNIVERSITY   (Germany)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^j UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^k UNIVERSITY OF AMSTERDAM   (Netherlands)

^l Labor Dr Krause and Kollegen MVZ GmbH   (Germany)

^m CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁿ Zentrales Inst Sanitatsdienstes B   (Germany)

^o Dezernat Tropenmedizin   (Germany)

more..

Author keywords

clinical disease; cutaneous; diagnosis; epidemiology; guideline; leishmaniasis; mucocutaneous; treatment

Indexed keywords

ALLOPURINOL; ANTIMONY; COSMETIC; FLUCONAZOLE; KETOCONAZOLE; METHYLBENZETHONIUM CHLORIDE; MILTEFOSINE; PAROMOMYCIN; ANTIPARASITIC AGENT; DERMATOLOGICAL AGENT;

ALGORITHM; ARTICLE; CLINICAL TRIAL (TOPIC); CONSENSUS; CRYOTHERAPY; EVIDENCE BASED MEDICINE; GERMANY; GOLD STANDARD; HEALTH CARE PLANNING; HUMAN; HYPERTHERMIC THERAPY; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIA TROPICA; LEISHMANIASIS; LOCAL THERAPY; LYMPHANGITIS; MEDICAL SOCIETY; MEDLINE; PARASITE VIRULENCE; PREGNANT WOMAN; PROGNOSIS; SKIN LEISHMANIASIS; STRAIN DIFFERENCE; SYSTEMIC THERAPY; TROPICAL MEDICINE; DERMATOLOGY; FEMALE; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATION; STANDARD;

ANTIPARASITIC AGENTS; DERMATOLOGIC AGENTS; DERMATOLOGY; FEMALE; GERMANY; HUMANS; LEISHMANIASIS, MUCOCUTANEOUS; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC;

EID: 80755143430     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0379.2011.07820.x     Document Type: Article

References (291)

1. Grimaldi, G. and J. Schottelius, Leishmaniases - their relationships to monoxenous and dixenous trypanosomatids. Med Microbiol Immunol, 2001. 190(1-2): p. 3-8. (Pubitemid 33079348)
2. Bogdan, C., et al., Visceral leishmaniasis in a German child who had never entered a known endemic area: case report and review of the literature. Clin Infect Dis, 2001. 32(2): p. 302-6. (Pubitemid 32524804)
3. Naucke, T.J., et al., Sandflies and leishmaniasis in Germany. Parasitol Res, 2008. 103 Suppl 1: p. S65-8.
4. Anonymous, WHO Working to overcome the global impact of neglected tropical diseases. First WHO report on neglected tropical diseases. 2010(978 92 4 1564090): p. 91-96.
5. Pratlong, F., et al., Geographical distribution and epidemiological features of Old World cutaneous leishmaniasis foci, based on the isoenzyme analysis of 1048 strains. Trop Med Int Health, 2009. 14(9): p. 1071-85.
6. Anonymous, Control of leishmaniasis. Report of a WHO Expert Committee. Geneva. 1990(Technical Report Series, No. 793).
7. Bailey, M.S. and D.N. Lockwood, Cutaneous leishmaniasis. Clin Dermatol, 2007. 25(2): p. 203-11. (Pubitemid 46366603)
8. Gurel, M.S., M. Ulukanligil, and H. Ozbilge, Cutaneous leishmaniasis in Sanliurfa: epidemiologic and clinical features of the last four years (1997- 2000). Int J Dermatol, 2002. 41(1): p. 32-7. (Pubitemid 34192972)
9. Myles, O., et al., Visceral leishmaniasis: clinical observations in 4 US army soldiers deployed to Afghanistan or Iraq, 2002-2004. Arch Intern Med, 2007. 167(17): p. 1899-901. (Pubitemid 47481486)
10. Magill, A.J., Cutaneous leishmaniasis in the returning traveler. Infect Dis Clin North Am, 2005. 19(1): p. 241- 66, x-xi. (Pubitemid 40208584)
11. Weiss, F., et al., Leishmania tropicainduced cutaneous and presumptive concomitant viscerotropic leishmaniasis with prolonged incubation. Arch Dermatol, 2009. 145(9): p. 1023-6.
12. Dillon, D.C., et al., Characterization of a Leishmania tropica antigen that detects immune responses in Desert Storm viscerotropic leishmaniasis patients. Proc Natl Acad Sci U S A, 1995. 92(17): p. 7981-5.
13. Grogl, M., et al., Survivability and infectivity of viscerotropic Leishmania tropica from Operation Desert Storm participants in human blood products maintained under blood bank conditions. Am J Trop Med Hyg, 1993. 49(3): p. 308-15. (Pubitemid 23289388)
14. From the Centers for Disease Control. Viscerotropic leishmaniasis in persons returning from Operation Desert Storm - 1990-1991. JAMA, 1992. 267(11): p. 1444-6.
15. Viscerotropic leishmaniasis in persons returning from Operation Desert Storm - 1990-1991. MMWR Morb Mortal Wkly Rep, 1992. 41(8): p. 131-4.
16. Zerpa, O., et al., Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. Br J Dermatol, 2007. 156(6): p. 1328-35. (Pubitemid 47029811)
17. Salman, S.M., N.G. Rubeiz, and A.G. Kibbi, Cutaneous leishmaniasis: clinical features and diagnosis. Clin Dermatol, 1999. 17(3): p. 291-6. (Pubitemid 29497893)
18. Carvalho, E.M., et al., Clinical and immunopathological aspects of disseminated cutaneous leishmaniasis. Acta Trop, 1994. 56(4): p. 315-25. (Pubitemid 24141548)
19. Costa, J.M., et al., Disseminated cutaneous leishmaniasis in a field clinic in Bahia, Brazil: a report of eight cases. J Trop Med Hyg, 1986. 89(6): p. 319-23. (Pubitemid 17230044)
20. Turetz, M.L., et al., Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J Infect Dis, 2002. 186(12): p. 1829-34. (Pubitemid 35463517)
21. Reithinger, R., et al., Cutaneous leishmaniasis. Lancet Infect Dis, 2007. 7(9): p. 581-96. (Pubitemid 47277438)
22. Weitzel, T., et al., Imported leishmaniasis in Germany 2001-2004: data of the SIMPID surveillance network. Eur J Clin Microbiol Infect Dis, 2005. 24(7): p. 471-6. (Pubitemid 41124499)
23. Harms, G., G. Schonian, and H. Feldmeier, Leishmaniasis in Germany. Emerg Infect Dis, 2003. 9(7): p. 872-5. (Pubitemid 36801592)
24. Ramirez, J.R., et al., Diagnosis of cutaneous leishmaniasis in Colombia: the sampling site within lesions influences the sensitivity of parasitologic diagnosis. J Clin Microbiol, 2000. 38(10): p. 3768-73.
25. Herwaldt, B.L., Leishmaniasis. Lancet, 1999. 354(9185): p. 1191-9. (Pubitemid 29460458)
26. Matsumoto, T., et al., Comparison of PCR results using scrape/exudate, syringe-sucked fluid and biopsy samples for diagnosis of cutaneous leishmaniasis in Ecuador. Trans R Soc Trop Med Hyg, 1999. 93(6): p. 606-7. (Pubitemid 30015784)
27. Bensoussan, E., et al., Comparison of PCR assays for diagnosis of cutaneous leishmaniasis. J Clin Microbiol, 2006. 44(4): p. 1435-9.
28. Weigle, K.A., et al., Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: a comparison of seven methods. Am J Trop Med Hyg, 1987. 36(3): p. 489-96. (Pubitemid 17099459)
29. Navin, T.R., et al., Cutaneous leishmaniasis in Guatemala: comparison of diagnostic methods. Am J Trop Med Hyg, 1990. 42(1): p. 36-42. (Pubitemid 20060509)
30. Aviles, H., et al., PCR detection and identification of Leishmania parasites in clinical specimens in Ecuador: a comparison with classical diagnostic methods. J Parasitol, 1999. 85(2): p. 181-7. (Pubitemid 29251830)
31. Belli, A., et al., Widespread atypical cutaneous Leishmaniasis caused by Leishmania (L.) Chagasi in Nicaragua. Am J Trop Med Hyg, 1999. 61(3): p. 380-5. (Pubitemid 29428705)
32. Al-Jawabreh, A., et al., Clinical diagnosis of cutaneous leishmaniasis: a comparison study between standardized graded direct microscopy and ITS1-PCR of Giemsa-stained smears. Acta Trop, 2006. 99(1): p. 55-61. (Pubitemid 44402243)
33. Schwartz, E., C. Hatz, and J. Blum, New world cutaneous leishmaniasis in travellers. Lancet Infect Dis, 2006. 6(6): p. 342-9. (Pubitemid 43737272)
34. Gomes, Y.M., et al., Diagnosis of canine visceral leishmaniasis: biotechnological advances. Vet J, 2008. 175(1): p. 45-52. (Pubitemid 351187518)
35. Muller, N., et al., PCR-based detection of canine Leishmania infections in formalin-fixed and paraffin-embedded skin biopsies: elaboration of a protocol for quality assessment of the diagnostic amplification reaction. Vet Parasitol, 2003. 114(3): p. 223-9. (Pubitemid 36645221)
36. Ergin, M., et al., Cutaneous leishmaniasis: evaluation by polymerase chain reaction in the Cukurova region of Turkey. J Parasitol, 2005. 91(5): p. 1208-11. (Pubitemid 41735045)
37. Vergel, C., J. Walker, and N.G. Saravia, Amplification of human DNA by primers targeted to Leishmania kinetoplast DNA and post-genome considerations in the detection of parasites by a polymerase chain reaction. Am J Trop Med Hyg, 2005. 72(4): p. 423-9. (Pubitemid 41278852)
38. Lima, H.C., J.A. Bleyenberg, and R.G. Titus, A simple method for quantifying Leishmania in tissues of infected animals. Parasitol Today, 1997. 13(2): p. 80-2. (Pubitemid 27080903)
39. Hepburn, N.C., Cutaneous leishmaniasis: current and future management. Expert Rev Anti Infect Ther, 2003. 1(4): p. 563-70. (Pubitemid 38855121)
40. Gaze, S.T., et al., Mucosal leishmaniasis patients display an activated inflammatory T-cell phenotype associated with a nonbalanced monocyte population. Scand J Immunol, 2006. 63(1): p. 70-8.
41. Gomes-Silva, A., et al., Can interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection? Clin Exp Immunol, 2007. 149(3): p. 440-4. (Pubitemid 47256154)
42. Landmann, E., et al., [Leishmaniasis with cutaneous and visceral involvement in a 13-month old boy]. Klin Padiatr, 2000. 212(5): p. 266-7.
43. Magill, A.J., et al., Visceral infection due to Leishmania tropica in a veteran of Operation Desert Storm who presented presented 2 years after leaving Saudi Arabia. Clin Infect Dis, 1994. 19(4): p. 805-6. (Pubitemid 24301176)
44. Alborzi, A., et al., Isolation of Leishmania tropica from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran. Am J Trop Med Hyg, 2008. 79(3): p. 435-7.
45. Annonymous. Diagnostik und Therapie der viszeralen Leishmaniasis (Kala-Azar). 2006; Available from: ttp://www.uni-duesseldorf.de/AWMF/ll/index. html.
46. Bogdan, C., et al., Detection of potentially diagnostic leishmanial antigens by western blot analysis of sera from patients with kala-azar or multilesional cutaneous leishmaniasis. J Infect Dis, 1990. 162(6): p. 1417-8.
47. Gomes-Silva, A., et al., Serological reactivity of different antigenic preparations of Leishmania (Leishmania) amazonensis and the Leishmania braziliensis complex. Rev Soc Bras Med Trop, 2008. 41(2): p. 135-41. (Pubitemid 351872391)
48. Marques, M.J., et al., Comparison of polymerase chain reaction with other laboratory methods for the diagnosis of American cutaneous leishmaniasis: diagnosis of cutaneous leishmaniasis by polymerase chain reaction. Diagn Microbiol Infect Dis, 2006. 54(1): p. 37-43. (Pubitemid 41815186)
49. Marin, C., et al., Enzyme-linked immunosorbent assay for superoxide dismutase-excreted antigen in diagnosis of sylvatic and Andean cutaneous leishmaniasis of Peru. Am J Trop Med Hyg, 2009. 80(1): p. 55-60.
50. Barroso-Freitas, A.P., et al., Accuracy of an ELISA and indirect immunofluorescence for the laboratory diagnosis of American tegumentary leishmaniasis. Trans R Soc Trop Med Hyg, 2009. 103(4): p. 383-9.
51. Baum, K.F. and R.L. Berens Successful treatment of cutaneous leishmaniasis with allopurinol after failure of treatment with ketoconazole. Clin Infect Dis, 1994. 18(5): p. 13-5.
52. Minodier, P. and P. Parola, Cutaneous leishmaniasis treatment. Travel Med Infect Dis, 2007. 5(3): p. 150-8. (Pubitemid 46585958)
53. Asilian, A., et al., A randomized, placebo-controlled trial of a twoweek regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg, 1995. 53(6): p. 648-51. (Pubitemid 26036354)
54. Murray, H.W., et al., Advances in leishmaniasis. Lancet, 2005. 366(9496): p. 1561-77. (Pubitemid 41540115)
55. Dowlati, Y., Treatment of cutaneous leishmaniasis (Old World). Clin Dermatol, 1996. 14(5): p. 513-7. (Pubitemid 26327745)
56. Alrajhi, A.A., et al., Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med, 2002. 346(12): p. 891-5. (Pubitemid 34984637)
57. Navin, T.R., et al., Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis, 1992. 165(3): p. 528-34.
58. Gonzalez, U., et al., Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev, 2008(4): p. CD005067.
59. Aronson, N.E., et al., A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection. PLoS Negl Trop Dis, 2010. 4(3): p. e628.
60. Reithinger, R., et al., Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis, 2005. 40(8): p. 1148-55. (Pubitemid 40490240)
61. Sadeghian, G., M.A. Nilfroushzadeh, and F. Iraji, Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate. Clin Exp Dermatol, 2007. 32(4): p. 371-4. (Pubitemid 46828317)
62. Mohebali, M., et al., Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop, 2007. 103(1): p. 33-40. (Pubitemid 47078934)
63. van Thiel, P.P., et al., Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan. Clin Infect Dis, 2010. 50(1): p. 80-3.
64. Dandashli, A., Treatment of cutaneous Leishmaniasis with Fluconazole: a randomized double-blind, placebo-controlled trial. J Eur Acad Dermatol Venereol 2005. 19 (Supp.2): p. 35.31.
65. Weinrauch, L., R. Livshin, and J. el-On, Ketoconazole in cutaneous leishmaniasis. Br J Dermatol, 1987. 117(5): p. 666-8. (Pubitemid 18078456)
66. Alsaleh, Q.A., R. Dvorak, and A. Nanda, Ketoconazole in the treatment of cutaneous leishmaniasis in Kuwait. Int J Dermatol, 1995. 34(7): p. 495-7.
67. Salmanpour, R., F. Handjani, and M.K. Nouhpisheh, Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis. J Dermatolog Treat, 2001. 12(3): p. 159-62. (Pubitemid 33116878)
68. Esfandiarpour, I. and A. Alavi, Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Int J Dermatol, 2002. 41(8): p. 521-4. (Pubitemid 35021497)
69. Seeberger, J., S. Daoud, and J. Pammer, Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod. Int J Dermatol, 2003. 42(7): p. 576-9. (Pubitemid 36869158)
70. Sadeghian, G. and M.A. Nilforoushzadeh, Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int J Dermatol, 2006. 45(7): p. 819-21. (Pubitemid 43984390)
71. al-Fouzan, A.S., et al., Cutaneous leishmaniasis in Kuwait. Clinical experience with itraconazole. Int J Dermatol, 1991. 30(7): p. 519-21.
72. Dogra, J., et al., Cutaneous leishmaniasis in India. Clinical experience with itraconazole (R51 211 Janssen). Int J Dermatol, 1990. 29(9): p. 661-2.
73. Dogra, J. and V.N. Saxena, Itraconazole and leishmaniasis: a randomised double-blind trial in cutaneous disease. Int J Parasitol, 1996. 26(12): p. 1413-5. (Pubitemid 27062527)
74. Van den Enden, E., et al., Treatment of cutaneous leishmaniasis with oral itraconazole. Int J Dermatol, 1994. 33(4): p. 285-6. (Pubitemid 24137633)
75. Momeni, A.Z. and M. Aminjavaheri, Treatment of recurrent cutaneous Leishmaniasis. Int J Dermatol, 1995. 34(2): p. 129-33.
76. Neub, A., et al., Cutaneous infection with Leishmania infantum in an infant treated successfully with miltefosine. J Dtsch Dermatol Ges, 2008. 6(12): p. 1061-4.
77. Herwaldt, B.L., B.A. Arana, and T.R. Navin, The natural history of cutaneous leishmaniasis in Guatemala. J Infect Dis, 1992. 165(3): p. 518-27.
78. Ameen, M., Cutaneous leishmaniasis: therapeutic strategies and future directions. Expert Opin Pharmacother, 2007. 8(16): p. 2689-99. (Pubitemid 350193711)
79. Arana, B.A., et al., Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg, 2001. 65(5): p. 466-70. (Pubitemid 33134578)
80. el-On, J., et al., Topical treatment of cutaneous leishmaniasis in Belize: in vitro and in vivo studies with Leishmania mexicana. Int J Parasitol, 1993. 23(1): p. 121-7.
81. Weinrauch, L., et al., Topical treatment of New World cutaneous leishmaniasis in Belize: a clinical study. J Am Acad Dermatol, 1993. 29(3): p. 443-6. (Pubitemid 23260134)
82. Velasco-Castrejon, O., et al., Treatment of cutaneous leishmaniasis with localized current field (radio frequency) in Tabasco, Mexico. Am J Trop Med Hyg, 1997. 57(3): p. 309-12. (Pubitemid 27407268)
83. Saenz, R.E., H. Paz, and J.D. Berman, Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med, 1990. 89(2): p. 147-55. (Pubitemid 20254438)
84. Jolliffe, D.S., Cutaneous leishmaniasis from Belize - treatment with ketoconazole. Clin Exp Dermatol, 1986. 11(1): p. 62-8. (Pubitemid 16201376)
85. Garcia A, P.R., Santos I, Dos-Santos I, Montenegro. D, Lemos E, Pereira T, Uso do itraconazole em 26 paceintes portadores de leishmaniose tegumentar americana. Ann Bras Dermatol, 1990. 65(4): p. 201-203.
86. Dorlo, T.P., et al., Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother, 2008. 52(8): p. 2855-60.
87. Nacher, M., et al., Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol, 2001. 95(4): p. 331-6. (Pubitemid 32575486)
88. Roussel, M., et al., Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol, 2006. 100(4): p. 307-14. (Pubitemid 46952621)
89. Soto, J., et al., Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis, 2004. 38(9): p. 1266-72. (Pubitemid 38608569)
90. Gonzalez, U., et al., Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev, 2009(2): p. CD004834.
91. Martinez, S., M. Gonzalez, and M.E. Vernaza, Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Clin Infect Dis, 1997. 24(2): p. 165-9. (Pubitemid 27081538)
92. Martinez, S. and J.J. Marr, Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med, 1992. 326(11): p. 741-4.
93. Soto, J. and J. Berman, Treatment of New World cutaneous leishmaniasis with miltefosine. Trans R Soc Trop Med Hyg, 2006. 100 Suppl 1: p. S34-40. (Pubitemid 44490170)
94. Velez, I., et al., Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg, 2010. 83(2): p. 351-6.
95. Vega, J.C., et al., The efficacy of thermotherapy to treat cutaneous leishmaniasis in Colombia: a comparative observational study in an operational setting. Trans R Soc Trop Med Hyg, 2009. 103(7): p. 703-6.
96. Bafica, A., et al., American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline. Int J Dermatol, 2003. 42(3): p. 203-7. (Pubitemid 41709833)
97. Lessa, H.A., et al., Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg, 2001. 65(2): p. 87-9. (Pubitemid 32746963)
98. Machado, P.R., et al., Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis, 2007. 44(6): p. 788-93.
99. Mendonca, M.G., et al., Persistence of Leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure? J Infect Dis, 2004. 189(6): p. 1018-23. (Pubitemid 38373094)
100. Schubach, A., et al., Cutaneous scars in American tegumentary leishmaniasis patients: a site of Leishmania (Viannia) braziliensis persistence and viability eleven years after antimonial therapy and clinical cure. Am J Trop Med Hyg, 1998. 58(6): p. 824-7.
101. Wortmann, G.W., et al., Cutaneous leishmaniasis following local trauma: a clinical pearl. Clin Infect Dis, 2000. 31(1): p. 199-201. (Pubitemid 32268968)
102. Cruz, A., et al., Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis, 2007. 195(4): p. 602-8. (Pubitemid 46214405)
103. Morgan, D.J., et al., Cutaneous leishmaniasis during pregnancy: exuberant lesions and potential fetal complications. Clin Infect Dis, 2007. 45(4): p. 478-82. (Pubitemid 47204466)
104. Calza, L., et al., Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS. J Am Acad Dermatol, 2004. 50(3): p. 461-5. (Pubitemid 38316145)
105. Croft, S.L. and V. Yardley, Chemotherapy of leishmaniasis. Curr Pharm Des, 2002. 8(4): p. 319-42. (Pubitemid 34460464)
106. Berman, J.D., et al., Susceptibility of clinically sensitive and resistant Leishmania to pentavalent antimony in vitro. Am J Trop Med Hyg, 1982. 31(3 Pt 1): p. 459-65. (Pubitemid 12074608)
107. Berman, J.D., In vitro susceptibility of antimony-resistant Leishmania to alternative drugs. J Infect Dis, 1982. 145(2): p. 279. (Pubitemid 12177652)
108. Yardley, V., et al., The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg, 2005. 73(2): p. 272-5. (Pubitemid 41278697)
109. Hepburn, N.C., Cutaneous leishmaniasis: an overview. J Postgrad Med, 2003. 49(1): p. 50-4. (Pubitemid 36758268)
110. Mebrahtu, Y., et al., Visceral leishmaniasis unresponsive to pentostam caused by Leishmania tropica in Kenya. Am J Trop Med Hyg, 1989. 41(3): p. 289-94. (Pubitemid 19250154)
111. Sacks, D.L., et al., Indian kala-azar caused by Leishmania tropica. Lancet, 1995. 345(8955): p. 959-61.
112. Ponce, C., et al., Leishmania donovani chagasi: new clinical variant of cutaneous leishmaniasis in Honduras. Lancet, 1991. 337(8733): p. 67-70.
113. Siriwardana, H.V., et al., Leishmania donovani and cutaneous leishmaniasis, Sri Lanka. Emerg Infect Dis, 2007. 13(3): p. 476-8. (Pubitemid 46348136)
114. Schriefer, A., et al., Multiclonal Leishmania braziliensis population structure and its clinical implication in a region of endemicity for American tegumentary leishmaniasis. Infect Immun, 2004. 72(1): p. 508-14. (Pubitemid 38018212)
115. Roberts, W.L. and P.M. Rainey, Antileishmanial activity of sodium stibogluconate fractions. Antimicrob Agents Chemother, 1993. 37(9): p. 1842-6. (Pubitemid 23265539)
116. Herwaldt, B.L. and J.D. Berman, Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg, 1992. 46(3): p. 296-306.
117. Seaton, R.A., et al., Out-patient parenteral antimicrobial therapy - a viable ption for the management of cutaneous leishmaniasis. QJM, 1999. 92(11): p. 659-67. (Pubitemid 29515872)
118. Wortmann, G., et al., A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis, 2002. 35(3): p. 261-7. (Pubitemid 34800273)
119. Marsden, P.D., et al., High continuous antimony therapy in two patients with unresponsive mucosal leishmaniasis. Am J Trop Med Hyg, 1985. 34(4): p. 710-3. (Pubitemid 16237014)
120. Oster, C.N., et al., American cutaneous leishmaniasis: a comparison of three sodium stibogluconate treatment schedules. Am J Trop Med Hyg, 1985. 34(5): p. 856-60. (Pubitemid 16241045)
121. Arevalo, J., et al., Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis, 2007. 195(12): p. 1846-51. (Pubitemid 46870258)
122. Romero, G.A., et al., Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg, 2001. 65(5): p. 456-65. (Pubitemid 33134577)
123. Neal, R.A. and S. Allen, In vitro anti- Leishmanial activity of compounds in current clinical use for unrelated diseases. Drugs Exp Clin Res, 1988. 14(10): p. 621-8. (Pubitemid 19061750)
124. McBride, M.O., et al., Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate. Clin Infect Dis, 1995. 21(3): p. 710.
125. Hartzell, J.D., et al., Varicella zoster virus meningitis complicating sodium stibogluconate treatment for cutaneous leishmaniasis. Am J Trop Med Hyg, 2006. 74(4): p. 591-2. (Pubitemid 46774438)
126. Romero, G.A.S., Tratamento da leishmaniose mucosa com sulfato de aminosidine: resultados de dois anos de acompanhamento. Rev. Soc. Bras. Med. Trop, 1998. 31(6): p. 511-516. (Pubitemid 28541356)
127. Palacios, R., et al., Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg, 2001. 64(3-4): p. 187-93. (Pubitemid 32565849)
128. Delobel, P. and R. Pradinaud, Rhabdomyolysis associated with pentamidine isethionate therapy for American cutaneous leishmaniasis. J Antimicrob Chemother, 2003. 51(5): p. 1319-20. (Pubitemid 36622097)
129. Soto, J., et al., Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am J Trop Med Hyg, 1994. 50(1): p. 107-11. (Pubitemid 24059993)
130. Soto-Mancipe, J., M. Grogl, and J.D. Berman, Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis, 1993. 16(3): p. 417-25. (Pubitemid 23066954)
131. Low, A.C.R.M., P. Rose, and D.S. Ridley, An outbreak of cutaneous leishmaniasis in Guyana: epidemiology, clinical and laboratory aspects. Ann Trop Med Parasitol, 1983. 77(3): p. 255-60. (Pubitemid 13064743)
132. Paula, C.D.R.d., Estudo comparativo da eficácia de isotionato de pentamidina administrada em três doses durante uma semana e de N-metilglucamina 20 mgSbV/kg/dia durante 20 dias para o tratamento da forma cutânea da leishmaniose tegumentar americana. Rev. Soc. Bras. Med. Trop, 2003. 36(3): p. 365-371.
133. Lai, A.F.E.J., et al., Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam. Int J Dermatol, 2002. 41(11): p. 796-800.
134. van der Meide, W.F., et al., Evaluation of treatment with pentamidine for cutaneous leishmaniasis in Suriname. Int J Dermatol, 2009. 48(1): p. 52-8.
135. Andersen, E.M., et al., Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis. Am J Trop Med Hyg, 2005. 72(2): p. 133-7. (Pubitemid 41278895)
136. Jaureguiberry, S., G. Graby, and E. Caumes, Efficacy of short-course intramuscular pentamidine isethionate treatment on Old World localized cutaneous leishmaniasis in 2 patients. Clin Infect Dis, 2006. 42(12): p. 1812-3. (Pubitemid 43839458)
137. Hellier, I., et al., Treatment of Old World cutaneous leishmaniasis by pentamidine isethionate. An open study of 11 patients. Dermatology, 2000. 200(2): p. 120-3. (Pubitemid 30199325)
138. Lightburn, E., et al., [Management of American cutaneous leishmaniasis. Outcome apropos of 326 cases treated with high-dose pentamidine isethionate]. Med Trop (Mars), 2003. 63(1): p. 35-44. (Pubitemid 46420167)
139. Correia, D., et al., [Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis]. Rev Soc Bras Med Trop, 1996. 29(5): p. 447-53. (Pubitemid 26300355)
140. Escobar, P., et al., Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18- OCH(3) (edelfosine) and amphotericin B. Acta Trop, 2002. 81(2): p. 151-7. (Pubitemid 34093805)
141. Sanchez-Canete, M.P., et al., Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug. Antimicrob Agents Chemother, 2009. 53(4): p. 1305-13.
142. Soto, J., et al., Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis, 2001. 33(7): p. E57-61.
143. Soto, J. and P. Soto, Miltefosine: oral treatment of leishmaniasis. Expert Rev Anti Infect Ther, 2006. 4(2): p. 177-85.
144. Soto, J., et al., Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis, 2007. 44(3): p. 350-6. (Pubitemid 46147616)
145. Soto, J., et al., Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia. Am J Trop Med Hyg, 2009. 81(3): p. 387-9.
146. Soto, J., et al., Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg, 2008. 78(2): p. 210-1. (Pubitemid 351844550)
147. Zerpa, O., et al., Treatment of diffuse cutaneous leishmaniasis with miltefosine: a case report. Int J Dermatol, 2006. 45(6): p. 751-3. (Pubitemid 44056682)
148. Calvopina, M., et al., Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment. Am J Trop Med Hyg, 2006. 75(6): p. 1074-7. (Pubitemid 351627483)
149. Chrusciak-Talhari, A., et al., Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania Viannia guyanensis in Manaus, Brazil. Am J Trop Med Hyg, 2011. eingereicht.
150. Rahman, S.B., A. ul Bari, and N. Mumtaz, Miltefosine in cutaneous
151. Killingley, B., L.E. Lamb, and R.N. Davidson, Miltefosine to treat cutaneous leishmaniasis caused by Leishmania tropica. Ann Trop Med Parasitol, 2009. 103(2): p. 171-5.
152. Keynan, Y., et al., Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan. Can J Infect Dis Med Microbiol, 2008. 19(6): p. 394-6.
153. Stojkovic, M., et al., First case of typical Old World cutaneous leishmaniasis treated with miltefosine. Int J Dermatol, 2007. 46(4): p. 385-7. (Pubitemid 46585389)
154. Tappe, D., A. Muller, and A. Stich, Resolution of cutaneous old world and new world leishmaniasis after oral miltefosine treatment. Am J Trop Med Hyg, 2010. 82(1): p. 1-3.
155. Dorlo, T.P. and P.A. Kager, Pentamidine dosage: a base/salt confusion. PLoS Negl Trop Dis, 2008. 2(5): p. e225.
156. Calvopina, M., et al., Itraconazole in the treatment of New World mucocutaneous leishmaniasis. Int J Dermatol, 2004. 43(9): p. 659-63.
157. Croft, S.L., V. Yardley, and H. Kendrick, Drug sensitivity of Leishmania species: some unresolved problems. Trans R Soc Trop Med Hyg, 2002. 96 Suppl 1: p. S127-9. (Pubitemid 34846596)
158. Hepatitis and ketoconazole therapy. Br Med J (Clin Res Ed), 1981. 283(6298): p. 1058-9.
159. Ozgoztasi, O. and I. Baydar, A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey. Int J Dermatol, 1997. 36(1): p. 61-3. (Pubitemid 27139758)
160. Singh, S., R. Singh, and S. Sundar, Failure of ketoconazole in oriental sore in India. J Chemother, 1995. 7 Suppl 4: p. 202-3. (Pubitemid 26040499)
161. Singh, S., R. Singh, and S. Sundar, Failure of ketoconazole treatment in cutaneous leishmaniasis. Int J Dermatol, 1995. 34(2): p. 120-1.
162. Momeni, A.Z., M. Aminjavaheri, and M.R. Omidghaemi, Treatment of cutaneous leishmaniasis with ketoconazole cream. J Dermatolog Treat, 2003. 14(1): p. 26-9. (Pubitemid 36417424)
163. El-Sayed, M. and A.E. Anwar, Intralesional sodium stibogluconate alone or its combination with either intramuscular sodium stibogluconate or oral ketoconazole in the treatment of localized cutaneous leishmaniasis: a comparative study. J Eur Acad Dermatol Venereol, 2010. 24(3): p. 335-40.
164. Tallab, T.M., et al., Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate. Int J Dermatol, 1996. 35(8): p. 594-7 (Pubitemid 26261937)
165. Dogra, J. and N. Aneja, Leishmaniasis and itraconazole: a controlled clinical trial on cutaneous subtypes. Int J Antimicrob Agents, 1994. 4(4): p. 309-11.
166. Momeni, A.Z., et al., Treatment of cutaneous leishmaniasis with itraconazole. Randomized double-blind study. Arch Dermatol, 1996. 132(7): p. 784-6. (Pubitemid 26238866)
167. Morelli, P., et al., Itraconazole can be effective in the treatment of sporotrichoid leishmaniasis. J Travel Med, 2004. 11(5): p. 328-30. (Pubitemid 39482179)
168. Albanese, G., et al., Cutaneous leishmaniasis. Treatment with itraconazole. Arch Dermatol, 1989. 125(11): p. 1540-2.
169. White, J.M., et al., Cutaneous leishmaniasis: three children with Leishmania major successfully treated with itraconazole. Pediatr Dermatol, 2006.23(1): p. 78-80.
170. Nassiri-Kashani, M., et al., A randomized, double-blind, placebocontrolled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. J Eur Acad Dermatol Venereol, 2005. 19(1): p. 80-3. (Pubitemid 40268145)
171. Al-Mutairi, N., et al., Tropical medicine rounds: Treatment of Old World cutaneous leishmaniasis with dapsone, itraconazole, cryotherapy, and imiquimod, alone and in combination. Int J Dermatol, 2009. 48(8): p. 862-9.
172. Saleem, K. and A. Rahman, Comparison of oral itraconazole and intramuscular meglumine antimoniate in the treatment of cutaneous leishmaniasis. J Coll Physicians Surg Pak, 2007. 17(12): p. 713-6.
173. Rangel, H., et al., Naturally azoleresistant Leishmania braziliensis promastigotes are rendered susceptible in the presence of terbinafine: comparative study with azole-susceptible Leishmania mexicana promastigotes. Antimicrob Agents Chemother, 1996. 40(12): p. 2785-91. (Pubitemid 26404344)
174. Amato, V.S., et al., Use of itraconazole in the treatment of mucocutaneous leishmaniasis: a pilot study. Int J Infect Dis, 2000. 4(3): p. 153-7.
175. Consigli, J., et al., Cutaneous leishmaniasis: successful treatment with itraconazole. Int J Dermatol, 2006. 45(1): p. 46-9.
176. Zvulunov, A., S. Klaus, and D. Vardy, Fluconazole for the treatment of cutaneous leishmaniasis. N Engl J Med, 2002. 347(5): p. 370-1; author reply 370-1.
177. Morizot, G., et al., Healing of Old World cutaneous leishmaniasis in travelers treated with fluconazole: drug effect or spontaneous evolution? Am J Trop Med Hyg, 2007. 76(1): p. 48-52. (Pubitemid 351627801)
178. Ben Salah, A., et al., A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg, 1995. 53(2): p. 162-6.
179. el-Safi, S.H., et al., A double-blind clinical trial of the treatment of cutaneous leishmaniasis with paromomycin ointment. Trans R Soc Trop Med Hyg, 1990. 84(5): p. 690-1. (Pubitemid 20358582)
180. Iraji, F. and A. Sadeghinia, Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran. Ann Trop Med Parasitol, 2005. 99(1): p. 3-9.
181. Davidson, R.N., et al., Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med, 1994. 87(2): p. 75-81. (Pubitemid 24044213)
182. Brown, M., et al., Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol, 2005. 153(1): p. 203-5. (Pubitemid 41044552)
183. Amato, V.S., et al., Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. Acta Trop, 2004. 92(2): p. 127-32. (Pubitemid 39180014)
184. Paradisi, A., et al., Atypical multifocal cutaneous leishmaniasis in an immunocompetent patient treated by liposomal amphotericin B. J Infect, 2005. 51(5): p. e261-4. (Pubitemid 43008973)
185. Gunduz, K., et al., Recidivans cutaneous leishmaniasis unresponsive to liposomal amphotericin B (AmBisome). J Eur Acad Dermatol Venereol, 2000. 14(1): p. 11-3. (Pubitemid 32899314)
186. Wortmann, G.W., et al., Failure of amphotericin B lipid complex in the treatment of cutaneous leishmaniasis. Clin Infect Dis, 1998. 26(4): p. 1006-7. (Pubitemid 28180355)
187. Vardy, D., et al., Topical amphotericin B for cutaneous leishmaniasis. Arch Dermatol, 1999. 135(7): p. 856-7.
188. Konecny, P. and D.J. Stark, An Australian case of New World cutaneous leishmaniasis. Med J Aust, 2007. 186(6): p. 315-7. (Pubitemid 46534239)
189. Campos-Munoz, L., et al., [Leishmania braziliensis: report of a pediatric imported case with response to liposomal amphotericin B]. Actas Dermosifiliogr, 2007. 98(1): p. 42-4. (Pubitemid 46446680)
190. Solomon, M., et al., Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. J Am Acad Dermatol, 2007. 56(4): p. 612-6. (Pubitemid 46400168)
191. Mings, S., et al., Cutaneous leishmaniasis with boggy induration and simultaneous mucosal disease. Am J Trop Med Hyg, 2009. 80(1): p. 3-5.
192. del Rosal, T., et al., Successful treatment of childhood cutaneous leishmaniasis with liposomal amphotericin B: report of two cases. J Trop Pediatr, 2010. 56(2): p. 122-4.
193. Perez-Ayala, A., et al., Imported leishmaniasis: a heterogeneous group of diseases. J Travel Med, 2009. 16(6): p. 395-401.
194. Wortmann, G., et al., Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg, 2010. 83(5): p. 1028-33.
195. Mirzabeigi, M., et al., Reactivation of dormant cutaneous Leishmania infection in a kidney transplant patient. J Cutan Pathol, 2006. 33(10): p. 701-4. (Pubitemid 44536351)
196. Musa, A.M., et al., Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kalaazar dermal leishmaniasis (PKDL). Ann Trop Med Parasitol, 2005. 99(6): p. 563-9. (Pubitemid 41215648)
197. Guffanti, M., et al., Post-Kala-Azar dermal leishmaniasis in an HIV-1- infected woman: recovery after amphotericin B following failure of oral miltefosine. Am J Trop Med Hyg, 2008. 79(5): p. 715-8.
198. Amato, V.S., et al., Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B. Clin Infect Dis, 2007. 44(2): p. 311-2. (Pubitemid 46080001)
199. Nonata, R., R. Sampaio, and P.D. Marsden, Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with AmBisome. Trans R Soc Trop Med Hyg, 1997. 91(1): p. 77. (Pubitemid 27095508)
200. Rongioletti, F., G.E. Cannata, and A. Parodi, Leishmaniasis due to L. infantum presenting as macrocheilitis and responding to liposomal amphotericin B. Eur J Dermatol, 2009. 19(3): p. 281-2.
201. Lambertucci, J.R. and L.C. Silva, Mucocutaneous leishmaniasis treated with liposomal amphotericin B. Rev Soc Bras Med Trop, 2008. 41(1): p. 87-8. (Pubitemid 351463796)
202. Amato, V.S., et al., Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil. J Eur Acad Dermatol Venereol, 2009. 23(9): p. 1026-34.
203. Martinez, S., et al., The synergistic action of pyrazolopyrimidines and pentavalent antimony against Leishmania donovani and L. braziliensis. Am J Trop Med Hyg, 1988. 39(3): p. 250-5.
204. Momeni, A.Z. and M. Aminjavaheri, Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol. Eur J Dermatol, 2003. 13(1): p. 40-3. (Pubitemid 36228505)
205. Velez, I., et al., Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann Intern Med, 1997. 126(3): p. 232-6. (Pubitemid 27061579)
206. Grimaldi, G., Jr. and R.B. Tesh, Leishmaniases of the New World: current concepts and implications for future research. Clin Microbiol Rev, 1993. 6(3): p. 230-50. (Pubitemid 23231207)
207. LaFon, S.W., et al., Inosine analogs. Their metabolism in mouse L cells and in Leishmania donovani. J Biol Chem, 1985. 260(17): p. 9660-5.
208. Llanos-Cuentas, A., et al., Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clin Infect Dis, 1997. 25(3): p. 677-84. (Pubitemid 27392612)
209. D'Oliveira Junior, A., P.R. Machado, and E.M. Carvalho, Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis. Int J Dermatol, 1997. 36(12): p. 938-40. (Pubitemid 28053898)
210. Momeni, A.Z., M.R. Reiszadae, and M. Aminjavaheri, Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate. Int J Dermatol, 2002. 41(7): p. 441-3.
211. Mashood AA, H.K., Efficacy of allopurinol compared with pentostam in the treatment of old worls cutaneous leishmaniasis. JCPSP Journal of the College of Physicians and Surgeons, 2001. 11(6): p. 367-70.
212. Esfandiarpour, I. and S.H. Dabiri, Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study. Int J Dermatol, 2007. 46(8): p. 848-52. (Pubitemid 47162788)
213. de Sa Oliveira, T., et al., Action of pentoxifylline on experimental cutaneous leishmaniasis due to Leishmania (Leishmania) amazonensis. Mem Inst Oswaldo Cruz, 2000. 95(4): p. 477-82.
214. Schriefer, A., M.E. Wilson, and E.M. Carvalho, Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis. Curr Opin Infect Dis, 2008. 21(5): p. 483-8.
215. Amato, V.S., et al., Mucosal leishmaniasis . Current scenario and prospects for treatment. Acta Trop, 2008. 105(1): p. 1-9. (Pubitemid 350262798)
216. Zargari, O., Pentoxifylline: a drug with wide spectrum applications in dermatology. Dermatol Online J, 2008. 14(11): p. 2.
217. Ojha, R.P., D. Cervantes, and L.A. Fischbach, Oral pentoxifylline and pentavalent antimony for treatment of leishmaniasis: promising but inconclusive evidence of superiority, compared with antimony monotherapy. Clin Infect Dis, 2007. 45(8): p. 1104; author reply 1005-6. (Pubitemid 47580364)
218. el-On, J., et al., Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol, 1992. 27(2 Pt 1): p. 227-31.
219. el-On, J. and A.D. Hamburger, Topical treatment of New and Old World cutaneous leishmaniasis in experimental animals. Trans R Soc Trop Med Hyg, 1987. 81(5): p. 734-7. (Pubitemid 18070982)
220. El-On, J., et al., Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals. Antimicrob Agents Chemother, 1984. 26(5): p. 745-51. (Pubitemid 15211674)
221. El-On, J., M. Katz, and L. Weinrauch, Treatment of cutaneous leishmaniasis by photodynamic therapy. J Am Acad Dermatol, 2004. 50(6): p. e12; author reply e13.
222. El-On, J., et al., Topical treatment of cutaneous leishmaniasis. J Invest Dermatol, 1986. 87(2): p. 284-8. (Pubitemid 16041745)
223. el-On, J., et al., Topical treatment of cutaneous leishmaniasis. Br Med J (Clin Res Ed), 1985. 291(6504): p. 1280-1. (Pubitemid 16216823)
224. el-On, J., L. Weinrauch, and R. Livshin, [Cutaneous leishmaniasis: development of a new topical treatment]. Harefuah, 1986. 110(11): p. 583-5.
225. el-On, J., et al., Topical treatment of recurrent cutaneous leishmaniasis with ointment containing paromomycin and methylbenzethonium chloride. Br Med J (Clin Res Ed), 1985. 291(6497): p. 704-5. (Pubitemid 15238029)
226. Ei-On, J., G.P. Jacobs, and L. Weinrauch, Topical chemotherapy of cutaneous Leishmaniasis. Parasitol Today, 1988. 4(3): p. 76-81.
227. Ben Salah, A., et al., WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS NeglTrop Dis, 2009. 3(5): p. e432.
228. Jaafari, M.R., et al., Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice. Antimicrob Agents Chemother, 2009. 53(6): p. 2259-65.
229. Sundar, S., et al., Injectable paromomycin for Visceral leishmaniasis in India. N Engl J Med, 2007. 356(25): p. 2571-81. (Pubitemid 46961002)
230. Llanos-Cuentas, A., et al., Parenteral aminosidine is not effective for Peruvian mucocutaneous leishmaniasis. Am J Trop Med Hyg, 2007. 76(6): p. 1128-31. (Pubitemid 351837878)
231. Soto, J., et al., Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate. Clin Infect Dis, 1995. 20(1): p. 47-51.
232. Bryceson, A.D., A. Murphy, and A.H. Moody, Treatment of 'Old World' cutaneous leishmaniasis with aminosidine ointment: results of an open study in London. Trans R Soc Trop Med Hyg, 1994. 88(2): p. 226-8. (Pubitemid 24139698)
233. Kim, D.H., et al., Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis, 2009. 3(2): p. e381.
234. El-On, J. and G. Messer, Leishmania major: antileishmanial activity of methylbenzethonium chloride. Am J Trop Med Hyg, 1986. 35(6): p. 1110-6. (Pubitemid 17210107)
235. Asilian, A., et al., Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: doubleblind, randomized trial in the Islamic Republic of Iran. Bull World Health Organ, 2003. 81(5): p. 353-9. (Pubitemid 36644261)
236. Faghihi, G. and R. Tavakoli-kia, Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin Exp Dermatol, 2003. 28(1): p. 13-6 (Pubitemid 36197553)
237. Shazad, B., B. Abbaszadeh, and A. Khamesipour, Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Eur J Dermatol, 2005. 15(2): p. 85-7. (Pubitemid 40434631)
238. Shani-Adir, A., et al., Leishmania tropica in northern Israel: a clinical overview of an emerging focus. J Am Acad Dermatol, 2005. 53(5): p. 810-5. (Pubitemid 41501366)
239. Soto, J., et al., Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis, 1998. 26(1): p. 56-8. (Pubitemid 28068155)
240. Krause, G. and A. Kroeger, Topical treatment of American cutaneous leishmaniasis with paramomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador. Trans R Soc Trop Med Hyg, 1994. 88(1): p. 92-4. (Pubitemid 24068862)
241. Armijos, R.X., et al., Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop, 2004. 91(2): p. 153-60. (Pubitemid 38952716)
242. Bailey, M.S., et al., Clinical guidelines for the management of cutaneous leishmaniasis in British military personnel. J R Army Med Corps, 2005. 151(2): p. 73-80.
243. Blum, J., et al., Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother, 2004. 53(2): p. 158-66. (Pubitemid 38239944)
244. Khatami, A., et al., Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol, 2007. 57(2): p. 335 e1-29.
245. el Darouti, M.A. and S.M. al Rubaie, Cutaneous leishmaniasis. Treatment with combined cryotherapy and intralesional stibogluconate injection. Int J Dermatol, 1990. 29(1): p. 56-9. (Pubitemid 20136326)
246. Gurei, M.S., et al., Efficacy of cryotherapy and intralesional pentostam in treatment of cutaneous leishmaniasis. J Egypt Soc Parasitol, 2000. 30(1): p. 169-76.
247. Nagaty, I.M. and A.H. Lashin, Treatment of cutaneous leishmaniasis patients with pentostam via intralesion infiltration. J Egypt Soc Parasitol, 2000. 30(1): p. 177-82.
248. Faris, R.M., et al., Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony. Int J Dermatol, 1993. 32(8): p. 610-2. (Pubitemid 23274595)
249. Sharma, N.L., et al., Localized cutaneous leishmaniasis due to Leishmania donovani and Leishmania tropica: preliminary findings of the study of 161 new cases from a new endemic focus in himachal pradesh, India. Am J Trop Med Hyg, 2005. 72(6): p. 819-24.
250. Sharquie, K.E., K.K. Al-Talib, and A.C. Chu, Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. Br J Dermatol, 1988. 119(1): p. 53-7.
251. Layegh, P., et al., Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children. Am J Trop Med Hyg, 2009. 80(2): p. 172-5.
252. Salmanpour, R., M.R. Razmavar, and N. Abtahi, Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis. Int J Dermatol, 2006. 45(9): p. 1115-6. (Pubitemid 44317140)
253. Mujtaba, G. and M. Khalid, Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis. Int J Dermatol, 1999. 38(8): p. 607-9. (Pubitemid 29404793)
254. Gadelha, A.d.R.O., Wandbergh Caldas de; Assunçäo, Irineide de Jesus; Dourado, Heitor Vieira., Tratamento da leishmaniose tegumentar americana com a pentamidina, esquema em dose única endovenosa/Treatment of american cutaneous Leishmaniasis with pentamidine: scheme in single endovenous dosis. An. bras. dermatol, 1990. 65(4): p. 198-200.
255. Uzun, S., et al., Clinical features, epidemiology, and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: recent experience in Turkey. J Parasitol, 2004. 90(4): p. 853-9.
256. Asilian, A., et al., The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. Ann Trop Med Parasitol, 2003. 97(5): p. 493-8.
257. Asilian, A., et al., Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol, 2004. 43(4): p. 281-3. (Pubitemid 38559545)
258. Solomon, M., et al., Treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate. J Eur Acad Dermatol Venereol, 2009. 23(10): p. 1189-92.
259. Alkhawajah, A.M., et al., Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration. Ann Trop Med Parasitol, 1997. 91(8): p. 899-905.
260. Oliveira-Neto, M.P., et al., Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil - an area of Leishmania (V.) braziliensis transmission. Int J Dermatol, 1997. 36(6): p. 463-8. (Pubitemid 27319639)
261. Navin, T.R., et al., Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg, 1990. 42(1): p. 43-50. (Pubitemid 20060510)
262. Junaid, A.J., Treatment of cutaneous leishmaniasis with infrared heat. Int J Dermatol, 1986. 25(7): p. 470-2. (Pubitemid 16025330)
263. Aram, H. and V. Leibovici, Ultrasound-induced hyperthermia in the treatment of cutaneous leishmaniasis.Cutis, 1987. 40(4): p. 350-3.
264. Babajev, K.B., O.G. Babajev, and V.I. Korepanov, Treatment of cutaneous leishmaniasis using a carbon dioxide laser. Bull World Health Organ, 1991. 69(1): p. 103-6.
265. Neva, F.A., et al., Observations on local heat treatment for cutaneous leishmaniasis. Am J Trop Med Hyg, 1984.33(5): p. 800-4. (Pubitemid 15201690)
266. Sacks, D.L., A. Barral, and F.A. Neva,Thermosensitivity patterns of Old vs. New World cutaneous strains of Leishmania growing within mouse peritoneal macrophages in vitro. Am J Trop Med Hyg, 1983. 32(2): p. 300-4.
267. Berman, J.D. and F.A. Neva, Effect of temperature on multiplication of Leishmania amastigotes within human monocyte-derived macrophages in vitro. Am J Trop Med Hyg, 1981. 30(2): p. 318-21. (Pubitemid 11117216)
268. Lobo, I.M., et al., Heat therapy for cutaneous leishmaniasis elicits a systemic cytokine response similar to that of antimonial (Glucantime) therapy. Trans R Soc Trop Med Hyg, 2006. 100(7): p. 642-9.
269. Sharquie, K.E., H. al-Hamamy, and D. el-Yassin, Treatment of cutaneous leishmaniasis by direct current electrotherapy: the Baghdadin device. J Dermatol, 1998. 25(4): p. 234-7. (Pubitemid 28216917)
270. Wortmann, G., Boiling the boil. Clin Infect Dis, 2005. 40(8): p. 1156-8. (Pubitemid 40490241)
271. Levine, N., Cutaneous leishmaniasis treated with controlled localized heating. Arch Dermatol, 1992. 128(6): p. 759-61.
272. Mosleh, I.M., et al., Efficacy of a weekly cryotherapy regimen to treat Leishmania major cutaneous leishmaniasis. J Am Acad Dermatol, 2008. 58(4): p. 617-24.
273. Leibovici, V. and H. Aram, Cryotherapy in acute cutaneous leishmaniasis. Int J Dermatol, 1986. 25(7): p. 473-5. (Pubitemid 16025331)
274. al-Majali, O., et al., A 2-year study of liquid nitrogen therapy in cutaneous leishmaniasis. Int J Dermatol, 1997. 36(6): p. 460-2. (Pubitemid 27319638)
275. Panagiotopoulos, A., et al., Treatment of cutaneous leishmaniasis with cryosurgery. Int J Dermatol, 2005. 44(9): p. 749-52. (Pubitemid 41301009)
276. Asilian, A. and M. Davami, Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo- controlled, randomized clinical trial. Clin Exp Dermatol, 2006. 31(5): p. 634-7. (Pubitemid 44086787)
277. Enk, C.D., et al., Treatment of cutaneous leishmaniasis with photodynamic therapy. Arch Dermatol, 2003. 139(4): p. 432-4. (Pubitemid 36427606)
278. Gardlo, K., et al., Treatment of cutaneous leishmaniasis by photodynamic therapy. J Am Acad Dermatol, 2003.48(6): p. 893-6. (Pubitemid 36706223)
279. Sohl, S., et al., Photodynamic treatment of cutaneous leishmaniasis. J Dtsch Dermatol Ges, 2007. 5(2): p. 128-30. (Pubitemid 46212729)
280. Pizinger, K., et al., Successful treatment of cutaneous leishmaniasis by photodynamic therapy and cryotherapy. Eur J Dermatol, 2009. 19(2):p. 172-3.
281. Miranda-Verastegui, C., et al., Randomized, double-blind clinical trial of topical imiquimod 5 % with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis, 2005. 40(10): p. 1395-403. (Pubitemid 40628625)
282. Arevalo, I., et al., Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis, 2007. 44(12): p. 1549-54. (Pubitemid 46871500)
283. Miranda-Verastegui, C., et al., Firstline therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl Trop Dis, 2009. 3(7): p. e491.
284. Firooz, A., et al., Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol, 2006. 142(12): p. 1575-9. (Pubitemid 44969213)
285. El-On, J., E. Bazarsky, and R. Sneir, Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod. Exp Parasitol, 2007. 116(2): p. 156-62. (Pubitemid 46602257)
286. Arevalo, I., et al., Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis, 2001. 33(11): p. 1847-51. (Pubitemid 33105123)
287. Kochar, D.K., et al., A double blind, randomised placebo controlled trial of rifampicin with omeprazole in the treatment of human cutaneous leishmaniasis. J Vector Borne Dis, 2006. 43(4): p. 161-7. (Pubitemid 44901458)
288. Kochar, D.K., et al., The role of rifampicin in the management of cutaneous leishmaniasis. QJM, 2000. 93(11): p. 733-7.
289. Almeida, R.P., et al., Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials. Am J Trop Med Hyg, 2005. 73(1): p. 79-81. (Pubitemid 41278752)
290. Layegh, P., et al., Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Am J Trop Med Hyg, 2007. 77(1): p. 99-101. (Pubitemid 351844358)
291. Prata, A., et al., Efficacy of azithromycin in the treatment of cutaneous leishmaniasis. Rev Soc Bras Med Trop, 2003. 36(1): p. 65-9. (Pubitemid 36648215)